Pharmaceutical company EpiCept Corp. (EPCT) said the U.S. FDA indicated that the company had necessary pivotal data to file a New Drug Application, or NDA, for Ceplene in combination with interleukin-2 as a remission maintenance treatment of acute myeloid leukemia.
The company noted that at a pre-NDA meeting last week, the U.S. regulatory body issued guidance [...]